This phase II trial studies how well poziotinib works in treating patients with non-small
lung cancer with EGFR or HER2 exon 20 mutation that is stage IV or has come back. Poziotinib
may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
Lung Cancer Research Foundation National Cancer Institute (NCI) Spectrum Pharmaceuticals, Inc